Susanne Marschner

Ligation of human CD4 interferes with antigen-induced activation of primary T cells.

CXCR4 engagement is required for HIV-1-induced L-selectin shedding.

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.

Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.

Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.

White blood cell inactivation after treatment with riboflavin and ultraviolet light.

The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(Mirasol®)-Treated Platelets Collected by Plateletpheresis.

Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions.

Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation.

In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood.

Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.

The inositol 5-phosphatase SHIP-1 and adaptors Dok-1 and 2 play central roles in CD4-mediated inhibitory signaling.

Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?

Development of a riboflavin and ultraviolet light-based device to treat whole blood.

Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice.

Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients.

Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.

Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.

Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment.

Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice.